**
In a significant revelation, internal records have disclosed that top officials from the US Environmental Protection Agency (EPA) convened with Bayer’s CEO, Bill Anderson, to discuss ongoing litigation surrounding glyphosate, a herbicide linked to cancer claims. This meeting, held on 17 June 2025, occurred just prior to a series of actions taken by the Trump administration aimed at bolstering Bayer’s position in the courts, raising questions about the intersection of corporate influence and regulatory oversight.
High-Stakes Meeting
The EPA meeting included prominent figures such as Lee Zeldin, the agency’s administrator, and other key executives from Bayer. The discussions were centred on “litigation issues” and notably included “supreme court action” regarding glyphosate, the active ingredient in popular herbicides like Roundup. This event unfolded amidst a backdrop of numerous lawsuits alleging that Bayer failed to adequately warn consumers about the cancer risks associated with its products.
These lawsuits, involving thousands of claimants, assert that Bayer’s glyphosate-based herbicides are responsible for various cancer diagnoses. The crux of Bayer’s defence hinges on the argument that if the EPA does not mandate a cancer warning on glyphosate labels, the company cannot be held liable for any alleged health risks. While some courts have sided with Bayer’s interpretation, others have rejected this argument, including the Biden administration’s solicitor general.
Administration Support Following the Meeting
Following the June meeting, the Trump administration took several measures supportive of Bayer’s legal stance. In a filing dated 1 December, Solicitor General D. John Sauer advocated for the Supreme Court to consider Bayer’s case, which the Court subsequently agreed to hear, scheduling a session for 27 April 2026. Furthermore, in February 2026, the White House invoked the Defense Production Act to safeguard the production of glyphosate and extend immunity to its manufacturers, including Bayer. A supportive amicus brief was filed with the Supreme Court on 2 March, outlining the government’s backing of Bayer’s position.
Bayer has characterised the meeting as a routine part of the regulatory process, asserting its transparency regarding ongoing litigation. “Such interactions are not limited to registrant companies,” Bayer stated, suggesting that other stakeholders, including non-governmental organisations, also engage with regulatory bodies.
Concerns Over Corporate Influence
The discussions surrounding the meeting have sparked considerable concern among advocacy groups and legal experts. Nathan Donley, environmental health science director for the Center for Biological Diversity, highlighted the disconcerting trend of regulatory agencies appearing more aligned with corporate interests than public health. “When the CEO of one of the largest companies in the world is meeting with political appointees in a US regulatory office, it shows just how much power and influence these corporations have on decisions that can have very real consequences for the health of all Americans,” he stated.
Legal expert Whitney Di Bona voiced similar apprehensions, questioning whether the EPA provides equal opportunities for victims of glyphosate exposure to voice their concerns in such regulatory discussions. Naomi Oreskes, a Harvard professor, remarked on the disturbing pattern of industry leaders having privileged access to government officials, contrasting it with the limited opportunities available to affected citizens.
Advocacy for Greater Transparency
Zen Honeycutt, founder of Moms Across America and a leader within the Make America Healthy Again movement, expressed her skepticism regarding the EPA’s responsiveness to public health concerns. She noted that while her organisation has sought dialogue with the EPA, the outcomes have been minimal, reinforcing a perception of systemic bias towards corporate interests.
In light of these developments, the transparency and accountability of the EPA remain critical issues, as the agency navigates the complexities of regulatory science and public health advocacy.
Why it Matters
The implications of this meeting are profound, as they highlight the potential for corporate influence to shape regulatory decisions that directly affect public health. As litigation against Bayer continues to unfold, the scrutiny of interactions between government agencies and corporate executives will be crucial in determining the future of pesticide regulation and the safety of agricultural practices. This situation underscores the need for a balanced approach that prioritises public health over corporate profit, ensuring that the voices of affected individuals are not drowned out in the halls of power.
